TRVI
$10.61-0.09 (-0.84%)
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF inte...
Recent News
Trevi Therapeutics Q4 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in two chronic cough programs. President and CEO Jennifer Good said 2025 marked a “major inflection po
Trevi Therapeutics (TRVI) Earnings Transcript
Jennifer Good: Good afternoon, and thank you for joining us for our fourth quarter 2025 earnings call and business update. Joining me today on this call are my colleagues, Dr. James Cassella, our Chief Development Officer; Farrell Simon, our Chief Commercial Officer; and David Hastings, our Chief Financial Officer.
Trevi Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Trevi Therapeutics, Inc.'s Q4 2025 earnings call
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Trevi Therapeutics Inc (TRVI) outlines pivotal trial plans and robust cash position, while addressing potential challenges in the IPF treatment landscape.
A Look At Trevi Therapeutics (TRVI) Valuation After FDA Green Light For Phase 3 Trials
Trevi Therapeutics (TRVI) shares are in focus after the company completed its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, clearing the way for two global Phase 3 trials of nalbuphine ER. See our latest analysis for Trevi Therapeutics. At a share price of US$11.01, Trevi’s 7 day share price return of 17.22% decline and 90 day share price return of 12.69% decline sit against a much stronger 1 year total shareholder return of 63.11%. This suggests that long term momentum...